SCHEMBL6283712

SCHEMBL6283712

NC(=O)c1cccc(Oc2ccc3c(C=Cc4ccccc4)n[nH]c3c2)c1

nearest known ligand 0.73

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.73
CHEK1 O14757 7/20 0.73
FGFR1 P11362 5/20 0.73
LCK P06239 1/20 0.71
CDK4 P11802 1/20 0.71
CCND1 P24385 1/20 0.71
CCND3 P30281 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5247993 0.85 KDR (1.00) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5247997 0.85 KDR (1.00) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5247427 0.84 KDR (1.00) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5247433 0.84 KDR (1.00) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5249781 0.84 KDR (0.82) KDRCHEK1FGFR1
SCHEMBL5249045 0.83 KDR (1.00) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5250160 0.83 KDR (1.00) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5250165 0.83 KDR (1.00) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5249432 0.83 KDR (1.00) KDRCHEK1FGFR1LCKCDK4
SCHEMBL5252259 0.81 KDR (1.00) KDRCHEK1FGFR1LCKCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6891044-B2 Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2005-05-10 US disclosed
EP-1218348-A2 INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2002-07-03 EP disclosed
WO-2001002369-A2 INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2001-01-11 WO disclosed